7th Antigen Specific Immune Tolerance Summit 2024

Memo

The 7th Antigen-Specific Immune Tolerance Drug Development Summit returns as the definitive, industry-dedicated forum bringing you the latest discoveries, preclinical, proof-of-concept, biomarker, and clinical development on tolerogenic therapies. Immune tolerance approaches have unprecedented potential to not only treat autoimmune diseases but to cure them; resetting the immune system is the most advantageous approach in biopharma's arsenal to trailblaze past standard immunosuppression treatments and create a new era of transformative therapies. With Diamyd's phase III trial for type I diabetes, COUR, Anokion, Imcyse, Takeda, and Selecta's phase II trials all underway, the field is on the precipice of advancing efficacious antigen-specific approaches for patients in need. URLs:Tickets: https://go.evvnt.com/2063192-2?pid=5569 Brochure: https://go.evvnt.com/2063192-3?pid=5569 Date and Time: On Mon, 18 Mar 2024 09:00 - Wed, 20 Mar 2024 15:30 Venue Details: Hilton Boston Back Bay, 40 Dalton Street, Boston, Massachusetts, 02115, United States Prices:Conference + 3 Workshops - Industry Pricing: USD 4197.00,Conference + 2 Workshops - Industry Pricing: USD 3797.00,Conference + 1 Workshop - Industry Pricing: USD 3398.00,Conference Only - Industry Pricing: USD 2999.00,Conference + 3 Workshops - Service Provider Pricing: USD 5097.00,Conference + 2 Workshops - Service Provider Pricing: USD 4631.00,Conference + 1 Workshop - Service Provider Pricing: USD 4166.00,Conference Only - Service Provider Pricing: USD 3699.00,Conference + 3 Workshops - Academic Pricing: USD 3597.00,Conference Only - Academic Pricing: USD 2599.00 Speakers: Aaron Winkler, Research Fellow, Immune Tolerance Lead, Inflammation and Immunology, Pfizer, Benjamin Cohn, Associate Director - Strategy and Business Development, Bristol Myers Squibb, Brad Hoffman, Professor, University of Florida, Brian Freed, Co-Founder and Chief Scientific Officer, RheumaGen, Charlotte Fribert, Chief Executive Officer, Toleranzia AB, Christof Gaunt, Founder in Residence - Immune Tolerance, Deep Science Ventures, Dan Mandell, Chief Executive Officer and Co-Founder, GRO Biosciences, David Easterhoff, Director, Immune Therapeutics Discovery, Moderna, Glennda Smithson, Director - Scientific and Translational Biomarker Research, Takeda Pharmaceutical Co. Ltd., Heather Denroche, Co-Founder and Director - Preclinical Development, Integrated Nanotherapeutics Inc., Jack Ragheb, Senior Vice President - Translational Sciences and Medicine, NexImmune Inc, Jean Van Rampelbergh, Chief Clinical Development Officer, Imcyse, Jose Carballido, Exec Director, Novartis AG, Joseph Podojil, Director - Immunology, Cour Pharmaceutical Development Company, Kei Kishimoto, Chief Scientific Officer, Selecta Biosciences Inc., Kevin White, Senior Director and Principal Scientist and Head Of Research, Exploratory Biology Immunology Discovery, Abbvie, Kristie Grebe, Chief Scientific Officer, Anokion Inc., Laura Cooney, Director - Biomarker Discovery Research and Autoimmunity, Immune Tolerance Network, Leonard L. Dragone, Chief Medical Officer, Abata Therapeutics, Mark Eisner, Chief Medical Officer, Sonoma Biotherapeutics, Michael Yeaman, Professor of Medicine, Chief of the Division of Molecular Medicine and Director of the Institute for Infection and Immunity, University of California, Navin Rao, Head of Adaptive immunity, Rheumatology and Autoantibody Discovery Area, Johnson and Johnson Services, Inc, Peter Strumph, Chief Executive Officer, Parvus Therapeutics, Pieter Rottiers, Chief Executive Officer, ActoBio Therapeutics NV, Rachel Hourigan, Researcher, Beacon, Saifur Rahman, Director - Immunology External Innovation, Sanofi, Terri Almos, Head of Emerging Science, Innovation, Inflammation and Immunology, Pfizer, Tobias Freitag, University Researcher, University of Helsinki